@PackGeneBiotech profile picture
PackGene Biotech @PackGeneBiotech

An international AAV packaging supplier. Aim to provide efficient, cost-effective, high-quality viral delivery solutions for gene and cell therapy.

Joined July 2022
  • Tweets 174
  • Following 20
  • Followers 33
105 Photos and videos
๐€๐€๐• ๐ ๐ž๐ง๐ž ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ ๐ฆ๐ข๐ฅ๐ž๐ฌ๐ญ๐จ๐ง๐ž ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž. ๐๐จ๐ซ๐ฐ๐š๐ฒ issued a reimbursement recommendation for ๐‡๐„๐Œ๐†๐„๐๐ˆ๐—. ๐…๐จ๐ฅ๐ฅ๐จ๐ฐ ๐๐š๐œ๐ค๐†๐ž๐ง๐ž ๐จ๐ง ๐‹๐ข๐ง๐ค๐ž๐๐ข๐ง lnkd.in/e5GY5tAR & ๐’๐ฎ๐›๐ฌ๐œ๐ซ๐ข๐›๐ž ๐ญ๐จ ๐Ž๐ฎ๐ซ ๐๐ž๐ฐ๐ฌ๐ฅ๐ž๐ญ๐ญ๐ž๐ซ.

๐๐จ๐ซ๐ฐ๐š๐ฒ Recommends ๐‡๐„๐Œ๐†๐„๐๐ˆ๐— Gene Therapy for Hemophilia B | PackGene Biotech, Inc....

๐Ÿงฌ ๐€๐€๐• ๐ ๐ž๐ง๐ž ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ ๐ฆ๐ข๐ฅ๐ž๐ฌ๐ญ๐จ๐ง๐ž ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž ๐๐จ๐ซ๐ฐ๐š๐ฒ has issued a positive reimbursement recommendation for ๐‡๐„๐Œ๐†๐„๐๐ˆ๐—ยฎ (etranacogene dezaparvovec)โ€”an ๐€๐€๐•5-?...

linkedin.com
6
๐Ÿ‘ Meet PackGene at #BSGCT2025 in London! ๐Ÿ—“๏ธJune 20 ๐Ÿ“Royal Holloway University Letโ€™s talk AAV, LVV, mRNA, & plasmid innovation with Xisha Huang. #GeneTherapy #Biotech #CDMO #PackGene
34
Weโ€™re heading to #EACR2025 in Lisbon! ๐Ÿ“Booth #17ย  ๐Ÿ—“๏ธย June 16โ€“19 Explore our full-service #CRO and #CDMO offerings: ๐Ÿงฌย AAV | Lentivirus | Plasmid | mRNA & LNP Letโ€™s talk cancer gene therapy innovation. ๐Ÿ“ฉย heng.hu@packgene.com #GeneTherapy #CancerResearch #Biotech #PackGene
24
๐Ÿ“ข Heading to #BIO2025 in Boston, June 16โ€“19? Meet PackGeneโ€™s CSO, Dr. Xin Swanson, to talk #GeneTherapy innovation. ๐Ÿ“Booth 387 โ€“ great science and conversations. Letโ€™s connect! #AAV #mRNA #Plasmid #CDMO #Biotech
12
Weโ€™re at #NVGCT2025 โŒ›๏ธJune 10โ€“11 in Lenteren, Netherland! Stop by the PackGene booth & meet Dr. Heng Hu to learn about our AAV, LVV, mRNA & plasmid platforms. packgene.com/event/nvgct-annโ€ฆ #GeneTherapy #Biotech #mRNA #AAV #PackGene

NVGCT Annual Conference, Lunteren, Netherland, June 10โ€“11, 2025 | PackGene Biotech

PackGene is proud to participate in this yearโ€™s meeting, where weโ€™ll showcase how our high-yield AAV and lentiviral vector platforms, mRNA-LNP technologies, and GMP-grade plasmid services are...

packgene.com
7
PackGene Biotech retweeted
Genetic Engineering & Biotechnology News@GENbio
28 May 2025
Conquering the Complexities of AAV Manufacturing: Advances in Efficiency, Scalability, Compliance GEN talked with several CDMOs and/or CROs about new ways they are addressing AAV manufacturing challenges. @PackGeneBiotech @CRiverLabs @LonzaGroup #AAV hubs.li/Q03prQ2j0

Conquering the Complexities of AAV Manufacturing: Advances in Efficiency, Scalability, Compliance

GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

genengnews.com
3
6
637
๐Ÿšจย PackGene is heading to #AACR2025! ๐ŸŽฏย Visit us at Booth 4346ย in Chicago, Apr 25โ€“30 ๐Ÿงฌย Discover how our AAV, lentiviral, and mRNA platforms are accelerating cancer research. ๐ŸŽย Stop by for a chat, insights, and free swag! ๐ŸŽ“ย Academic promo: packgene.com/promotion/acadeโ€ฆ #GeneTherapy
20
24-month data from Beacon Therapeutics' AGTC-501 HORIZON Trial for XLRP now in @AmerAcadOphth! Promising results in gene therapy. #GeneTherapy #RetinalDisease #XLRP #AAV #Packgene packgene.com/frontier/250319โ€ฆ

Beacon Therapeutics published 24-month safety and efficacy data from the AGTC-501 HORIZON Trial in...

Beacon Therapeutics announces the publication of 24-month data from the Phase 1/2 HORIZON trial of laru-zova (AGTC-501), a treatment for X-linked retinitis

packgene.com
47
Arbor Biotechnologies closes $73.9M Series C to advance ABO-101 for Primary Hyperoxaluria Type 1 (PH1). This milestone highlights the potential of CRISPR Cas12i2 and signals continued investor confidence in groundbreaking therapies. #GeneEditing #CRISPR packgene.com/frontier/250319โ€ฆ

Arbor Raises $73.9M Series C to Support Clinical Trials of ABO-101, a Novel Treatment for Primary...

Arbor Biotechnologies, a pioneering gene editing company established nine years ago by CRISPR luminary Feng Zhang, has successfully closed a $73.9 million

packgene.com
15
HUGE NEWS! Beam Therapeutics achieves FIRST-EVER clinical genetic correction in AATD trial! ย BEAM-302 shows: โœ… โฌ†๏ธย AAT levels (exceeding therapeutic threshold!) โœ… โฌ‡๏ธย 78% reduction in mutant Z-AAT! โœ…ย Corrected M-AAT production! โœ…ย Great safety profile! investors.beamtx.com/news-reโ€ฆ
23
Academic Discovery Engine Accelerate your research from design to delivery with academic-exclusive offers packgene.com/support/promotiโ€ฆ #AAV #ViralVector #CRISPR #ResearchOptimization
13
๐ŸงฌThis #RareDiseaseDay, weโ€™re breaking barriers in gene therapy! โœ…Advancing SPG56 & OTOF hearing loss treatments ๐Ÿ”—No patient left behind. Learn more: packgene.com/event/rare-diseโ€ฆ #GeneTherapy #RareDiseases #BreakingBarriers #PackGene
14
Allogene ($ALLO) gets FDA IND clearance for ALLO-329, an allogeneic CAR T for autoimmune diseases. Phase1 trial starts mid-2025 for lupus, myopathies, & systemic sclerosis. Targets CD19 B cells & CD70 T cells. Daggerยฎ tech may eliminate lymphodepletion. packgene.com/frontier/250131โ€ฆ

Allogene Therapeutics Announces FDA Clearance of IND Application for Rheumatology Basket Study |...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company advancing the development of allogeneic CAR T (AlloCAR Tโ„ข) therapies for

packgene.com
54
ELEVIDYS shows sustained benefits for 2 YEARS in ambulatory #DMD patients! Sarepta's EMBARK study delivers promising long-term data. โœจ packgene.com/frontier/250131โ€ฆ #RareDisease #GeneTherapy #AAV #Packgene #Sarepta

Sarepta Therapeutics Announces EMBARK Study Part 2 Results | PackGene Biotech

Sarepta Therapeutics announced positive topline results from Part 2 of the EMBARK (Study SRP-9001-301) Phase 3 clinical trial evaluating ELEVIDYS

packgene.com
1
50
Weโ€™re at #PMWC2025! Visit PackGene at Booth A421 to discuss our GMP viral (AAV)ย and non-viral solutions. Letโ€™s innovate together and shape the future of precision medicine. Booth A421โ€”see you there! #GeneTherapy #AAV #PrecisionMedicine #Biotech
1
1
123
Vertex & Orna team up to develop gene therapies for SCD & TDT! $65M upfront to boost RNA-based innovations using Orna's LNP tech. This collab drives progress toward better rare disease treatments. packgene.com/frontier/250110โ€ฆ #GeneTherapy #SCD #VertexPharma
30
A Global Alliance to Save Lives: How Two Parents and PackGene Are Redefining Whatโ€™s Possible in Gene Therapy with Help from Weill Cornell Medicine Read more๐Ÿ‘‰packgene.com/news/250107/ Video link: youtube.com/watch?v=QwlYjWxEโ€ฆ #GeneTherapy
18
Novartis' OAV101 IT gene therapy shows promise for type II SMA patients aged 2-17! ๐Ÿš€Favorable Phase III results could expand options for older pediatric patients. packgene.com/frontier/250109โ€ฆ #GeneTherapy #SMA #RareDisease
32
โœจMedical Breakthroughs of 2024โœจ ยท Enhertu & Tagrisso redefine cancer care ยท GLP-1 meds tackle obesity, heart disease, & sleep apnea ยท Lenacapavir: 100% HIV prevention ยท New treatments for Duchenne MD, schizophrenia & more packgene.com/frontier/202501โ€ฆ #GeneTherapy
1
109
GEMMABio raises $34M to advance #GeneTherapy for rare diseases! With strong partnerships and innovative approaches, theyโ€™re redefining treatment accessibility. packgene.com/frontier/241227โ€ฆ #HealthcareInnovation #RareDiseases
1
29
Load more